Sangamo BioSciences has inked a deal to provide Genentech with its zinc finger DNA-binding protein technology along with ZFP nucleases to generate cell lines with novel characteristics for protein pharmaceutical production purposes. The proteins regulate the work of genes in cells and can be targeted at specific genes linked to disease.
"We have engineered ZFNs to facilitate the efficient generation of production cell lines with altered traits," said Edward Lanphier, Sangamo's president and chief executive officer. "Our technology has the potential to change the speed and efficiency of cell engineering to meet the increased demand for proteins in a variety of industries including pharmaceutical protein manufacturing."
- check out the release on the deal
- here's the AP report for more information